Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion-Reference-Cited by-同舟云学术

Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

Published:2014-07 Issue:7 Volume:38 Page:781-787
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Eskazan Ahmet Emre^ORCID,Eyice Deniz,Kurt Enes Ali,Elverdi Tugrul,Yalniz Fevzi Firat,Salihoglu Ayse,Ar Muhlis Cem,Ongoren Aydin Seniz,Baslar Zafer,Ferhanoglu Burhan,Aydin Yildiz,Tuzuner Nukhet,Ozbek Ugur,Soysal Teoman

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias;Talpaz;N Engl J Med,2006

2. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia;McCormack;Drugs,2011

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N Engl J Med,2003

4. Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients;Sahin;Turk J Haematol.,2013

5. Resistance to imatinib: mutations and beyond;La Rosée;Semin Hematol,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials;Leukemia Research;2024-08

2. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04

3. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP;Pleura and Peritoneum;2024-02-28

5. Bosutinib – related pleural effusion in patients with chronic myeloid leukemia;Expert Opinion on Drug Safety;2021-01-08